Genocea Announces Wind Down of Operations and Delisting From NASDAQ
May 24, 2022 08:00 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its...
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives
April 28, 2022 16:05 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
April 08, 2022 13:05 ET
|
Genocea Biosciences, Inc.
GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward...
Genocea Biosciences to Host Investor Webinar
April 04, 2022 08:07 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced...
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 14, 2022 17:06 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
Genocea Provides Fourth Quarter 2021 Corporate Update
March 10, 2022 07:00 ET
|
Genocea Biosciences, Inc.
Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA),...
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
March 08, 2022 17:39 ET
|
Genocea Biosciences, Inc.
Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral T cell therapy for solid tumors The PLANET manufacturing process reliably...
John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors
March 07, 2022 16:05 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast
March 03, 2022 08:00 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth...
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 19:50 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...